+212.8%
RDDT vs MRNA
+37.8%
+175.0%
-61.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.6% | +5.4% | -3.8% | +1.4% |
| 7D | +2.1% | -1.1% | +3.2% | +2.2% |
| 30D | +2.8% | +126.1% | -123.3% | -2.4% |
| 3M | -8.9% | +190.0% | -199.0% | -17.4% |
| 6M | +15.1% | +157.2% | -142.2% | +6.1% |
| YTD | -31.4% | +388.2% | -419.6% | -43.5% |
| 1Y | -39.4% | +467.0% | -506.5% | -51.6% |
| All | +212.8% | +37.8% | +175.0% | +152.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling